Amivantamab, a bispecific antibody targeting both EGFR and MET, has been developed to inhibit these pathways simultaneously, aiming to overcome resistance mechanisms and improve treatment outcomes for patients with NSCLC [20]. The gene discussed is MET; the disease is non-small cell lung carcinoma.